Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study

Population-Based Study of Pseudoprogression after Chemoradiotherapy in GBM

(2014) Gloria B. Roldán et al.   CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

Pseudoprogression Following Chemoradiotherapy for Glioblastoma Multiforme

(2014) Paul Sanghera et al.   CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy

(2012) Søren Møller et al.   ACTA ONCOLOGICA

Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO)

(2012) Miguel J. Gil et al.   ANTI-CANCER DRUGS

A change in the apparent diffusion coefficient after treatment with bevacizumab is associated with decreased survival in patients with recurrent glioblastoma multiforme

(2012) M J Paldino et al.   BRITISH JOURNAL OF RADIOLOGY

Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria

(2012) J. G. Perez-Larraya et al.   NEURO-ONCOLOGY

Response Assessment in Neuro-Oncology Criteria: Implementation Challenges in Multicenter Neuro-Oncology Trials

(2011) W.B. Pope et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma

(2011) L.C. Hygino da Cruz et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Serial Magnetic Resonance Spectroscopy Reveals a Direct Metabolic Effect of Cediranib in Glioblastoma

(2011) H. Kim et al.   CANCER RESEARCH

Advances in MRI Assessment of Gliomas and Response to Anti-VEGF Therapy

(2011) Whitney B. Pope et al.   Current Neurology and Neuroscience Reports

Pseudoprogression: Relevance With Respect to Treatment of High-Grade Gliomas

(2011) James Fink et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Irinotecan and bevacizumab in recurrent glioblastoma multiforme

(2011) Jan Nyrop Jakobsen et al.   EXPERT OPINION ON PHARMACOTHERAPY

Cell invasion, motility, and proliferation level estimate (CIMPLE) maps derived from serial diffusion MR images in recurrent glioblastoma treated with bevacizumab

(2011) Benjamin M. Ellingson et al.   JOURNAL OF NEURO-ONCOLOGY

Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria

(2011) A. Radbruch et al.   NEURO-ONCOLOGY

Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab

(2011) B. M. Ellingson et al.   NEURO-ONCOLOGY

Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: Analysis of single-agent and combined modality approaches

(2011) Kathryn Beal et al.   Radiation Oncology

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab

(2010) M. Prados et al.   NEURO-ONCOLOGY

Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma

(2010) E. Essock-Burns et al.   NEURO-ONCOLOGY

Changes in Relative Cerebral Blood Volume 1 Month after Radiation-Temozolomide Therapy Can Help Predict Overall Survival in Patients with Glioblastoma

(2010) Rajiv Mangla et al.   RADIOLOGY

Response Assessment in Neuro-Oncology

(2010) Eudocia C. Quant et al.   Current Oncology Reports

A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients

(2009) A. Gregory Sorensen et al.   CANCER RESEARCH

Pseudoprogression and pseudoresponse: Challenges in brain tumor imaging

(2009) Jennifer L. Clarke et al.   Current Neurology and Neuroscience Reports

Pseudoprogression and pseudoresponse in the treatment of gliomas

(2009) Dieta Brandsma et al.   CURRENT OPINION IN NEUROLOGY

End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression

(2009) Elizabeth R. Gerstner et al.   JOURNAL OF NEURO-ONCOLOGY

Imaging response criteria for recurrent gliomas treated with bevacizumab: Role of diffusion weighted imaging as an imaging biomarker

(2009) Rajan Jain et al.   JOURNAL OF NEURO-ONCOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

FDA Drug Approval Summary: Bevacizumab (Avastin(R)) as Treatment of Recurrent Glioblastoma Multiforme

(2009) M. H. Cohen et al.   ONCOLOGIST

Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations

(2009) Cristo Chaskis et al.   SURGICAL NEUROLOGY

Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide

(2008) Walter Taal et al.   CANCER

MGMTPromoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients

(2008) Alba A. Brandes et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan

(2008) R. M. Zuniga et al.   JOURNAL OF NEURO-ONCOLOGY

Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases

(2008) Sheikh A. Ali et al.   JOURNAL OF NEUROSURGERY

Novel anti-angiogenic therapies for malignant gliomas

(2008) Andrew D Norden et al.   LANCET NEUROLOGY

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

(2008) Dieta Brandsma et al.   LANCET ONCOLOGY

Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology

(2008) Alba A. Brandes et al.   NEURO-ONCOLOGY

Experience with irinotecan for the treatment of malignant glioma

(2008) James J. Vredenburgh et al.   NEURO-ONCOLOGY

Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence

(2008) A. D. Norden et al.   NEUROLOGY

Response criteria for glioma

(2008) A Gregory Sorensen et al.   Nature clinical practice. Oncology